



HOKKAIDO UNIVERSITY

Title	Valosin-containing protein (VCP/p97) plays a role in the replication of West Nile virus
Author(s)	Phongphaew, Wallaya; Kobayashi, Shintaro; Sasaki, Michihito et al.
Citation	Virus Research, 228, 114-123 https://doi.org/10.1016/j.virusres.2016.11.029
Issue Date	2017-01-15
Doc URL	https://hdl.handle.net/2115/67761
Rights	© 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Rights(URL)	https://creativecommons.org/licenses/by-nc-nd/4.0/
Type	journal article
File Information	(77370) Valosin-containing protein and WNV.pdf



Valosin-containing protein (VCP/p97) plays a role in the replication of West Nile virus

Wallaya Phongphaew¹, Shintaro Kobayashi^{1,2}, Michihito Sasaki¹, Michael Carr^{3,4}, William W. Hall^{3,5,6}, Yasuko Orba¹ and Hirofumi Sawa^{1,3,6*}

¹ Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, N20, W10, Kita-ku, Sapporo, 001-0020, Japan

² Laboratory of Public Health, Graduate School of Veterinary Medicine, Hokkaido University, N18, W9, Kita-ku, Sapporo, 001-0020, Japan

³ Global Institution for Collaborative Researches and Education (GI-CoRE), Global Station for Zoonosis Control, Hokkaido University, N20, W10, Kita-ku, Sapporo, 001-0020, Japan

⁴ National Virus Reference Laboratory, University College Dublin, Belfield, Dublin 4, Ireland

⁵ Center for Research in Infectious Diseases, University College of Dublin, Belfield, Dublin 4, Dublin, Ireland

⁶ Global Virus Network (GVN), The Institute of Human Virology, University of Maryland, 22 S. Greene Street, Baltimore, MD 21201, USA

*Corresponding author: h-sawa@czc.hokudai.ac.jp

Abstract

Valosin-containing protein (VCP) is classified as a member of the type II AAA⁺ ATPase protein family. VCP functions in several cellular processes, including protein degradation, membrane fusion, vesicular trafficking and disassembly of stress granules. Moreover, VCP is considered to play a role in the replication of several viruses, albeit through different mechanisms. In the present study, we have investigated the role of VCP in West Nile virus (WNV) infection. Endogenous VCP expression was inhibited using either VCP inhibitors or by siRNA knockdown. It could be shown that the inhibition of endogenous VCP expression significantly inhibited WNV infection. The entry assay revealed that silencing of endogenous VCP caused a significant reduction in the expression levels of WNV-RNA compared to control siRNA-treated cells. This indicates that VCP may play a role in early steps either the binding or entry steps of the WNV life cycle. Using WNV virus like particles and WNV-DNA-based replicon, it could be demonstrated that perturbation of VCP expression decreased levels of newly synthesized WNV genomic RNA. These findings suggest that VCP is involved in early steps and during genome replication of the WNV life cycle.

Keywords: VCP, WNV replication, early steps, genome replication

1. Introduction

West Nile virus (WNV) belongs to genus the *Flavivirus*, family *Flaviviridae* and has an approximately 11 kb positive sense, single-stranded genomic RNA [(+)ssRNA]. The WNV genome encodes three structural proteins (C, prM and E) and seven non-structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5) (Brinton, 2014; Fields et al., 2013). Many species of mammals and birds can be infected by WNV (Dauphin et al., 2004; Egberink et al., 2015; Fields et al., 2013; Gamino et al., 2016; Kramer and Bernard, 2001; Lichtensteiger et al., 2003; Read et al., 2005) and infection causes West Nile fever and encephalitis in human and horses (Dauphin et al., 2004; Samuel and Diamond, 2006). WNV was firstly isolated from a Ugandan woman in 1937 (C. et al., 1940; Fields et al., 2013), but has now spread widely to many countries (Fields et al., 2013; Paz, 2015; Troupin and Colpitts, 2016). In the United States, approximately 44,000 cases of WNV infection were reported between 1999 and 2015 (CDC, 2016).

WNV attaches to host cells through the interaction of the viral E protein and cellular receptors on the surface of host cells (Fields et al., 2013). Several attachment receptors of WNV have been reported and include the laminin receptor (Bogachek et al., 2010; Perera-Lecoin et al., 2014; Zaitsev et al., 2014; Zidane et al., 2013), TIM (T cell/transmembrane, immunoglobulin and mucin) and TAM (Tyro3, Axl and Mer) families (Carnec et al., 2016; Morizono and Chen, 2014; Perera-Lecoin et al., 2014), DC-SIGN/L-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin) (Davis et al., 2006; Denizot et al., 2012; Martina et al., 2008; Shimojima et al., 2014) and integrin $\alpha v \beta 3$ (Bogachek et al., 2010; Fields et al., 2013; Perera-Lecoin et al., 2014; Smit et al., 2011; Zaitsev et al., 2014). Following attachment, the virus is then internalized into the cytoplasm *via* clathrin-mediated endocytosis (Brinton, 2014; Chu and Ng, 2004; Fields et al., 2013). WNV particles are delivered to early or intermediate endosomes, which mature into late endosomes, following a conformational change of the viral E protein dimer triggered by the acidic environment in late endosomes. Membrane fusion between viral particles and endosomal membranes then occurs and, thereafter, WNV genomic RNA is released into the cytosol, with

subsequent translation and replication (Chu et al., 2006; Chu and Ng, 2004; Fields et al., 2013; Heinz and Allison, 2000; Smit et al., 2011). Host cell membrane rearrangements are induced during replication of flaviviruses, including WNV, to coordinate the processes of genomic RNA replication and virus assembly. Viral genomic RNA replication is thought to occur in endoplasmic reticulum (ER) membrane-derived vesicles (in structures termed vesicle packets) (Gillespie et al., 2010; Kaufusi et al., 2014; Welsch et al., 2009). Encapsidation of nascent viral genomic RNA is achieved by the capsid protein and budding into the ER yielding a viral envelope coated with prM and E proteins (Brinton, 2014; Fields et al., 2013; Suthar et al., 2013; Welsch et al., 2009). The immature virions are transported *via* the host secretory pathway and virion maturation then occurs in the acidic compartments of the Golgi by cleavage of the prM protein by a furin-like protease (Plevka et al., 2014; Roby et al., 2015; Yu et al., 2008). Mature virions are then released from the infected cells through exocytosis (Fields et al., 2013; Samuel and Diamond, 2006). It has been reported that several cellular pathways and host factors are involved in WNV infection (Ambrose and Mackenzie, 2011; Brinton, 2014; Chahar et al., 2013; Chu and Ng, 2004; Courtney et al., 2012; Fernandez-Garcia et al., 2011; Fields et al., 2013; Gilfoy et al., 2009; Kobayashi et al., 2016a; Krishnan et al., 2008; Ma et al., 2015); however, the role of valosin-containing protein (VCP) has remained controversial.

VCP, also known as CDC48 in *Saccharomyces cerevisiae*, is well conserved among eukaryotes with orthologues in archaea, protozoa, insects and plants (Meyer et al., 2012; Wolf and Stolz, 2012), and is classified as a member of the type II AAA⁺ ATPase (adenosine triphosphatase-associated with diverse cellular activities) family (Koller and Brownstein, 1987; Pye et al., 2006; Stolz et al., 2011; Wolf and Stolz, 2012; Xia et al., 2016). VCP is a homohexameric complex composed of six protomers organized as two concentric-rings with a central pore. VCP conformational changes, driven by adenosine triphosphate hydrolysis, acts as a chaperone in protein homeostasis systems, which include ER-associated degradation (ERAD) (Wolf and Stolz, 2012; Xia et al., 2016; Zhong and Pittman, 2006) and mitochondria-associated degradation and autophagy

(Bug and Meyer, 2012; Dargemont and Ossareh-Nazari, 2012; Xia et al., 2016; Yamanaka et al., 2012) to prevent accumulation of misfolded-proteins and turnover of certain proteins. Recently, a role of VCP in the disassembly of stress granules (SGs) has also been reported (Buchan et al., 2013; Seguin et al., 2014). Generally, after removal of stress stimuli, SGs are disassembled by VCP and mRNA in the SGs could be restored allowing mRNA translation to proceed. Otherwise, depletion of VCP causes persistence of SGs leading to blockage of mRNA restoration and an arrest of mRNA translation (Buchan et al., 2013). It has also been reported that VCP is involved in chromatin-associated degradation and several nuclear substrates of VCP have been described (Maric et al., 2014; Verma et al., 2011; Wilcox and Laney, 2009). Furthermore, VCP also participates in membrane fusion and vesicular trafficking events (Bug and Meyer, 2012; Meyer et al., 2012; Ramanathan and Ye, 2012; Ritz et al., 2011; Xia et al., 2016). VCP binds to endocytic components, and silencing of VCP leads to a failure of maturation and enlargement of the early endosome (Ramanathan and Ye, 2012).

Interestingly, VCP has also been implicated in the life cycle of several (+)ssRNA viruses. It has been previously reported that VCP facilitates the replication of poliovirus (PV) (Arita et al., 2012). Depletion of VCP caused a reduction of PV infection, whereas, a mutant PV, which has a secretion inhibition-negative phenotype, increases the affinity of binding to VCP and resists VCP-knockdown compared to wild-type PV, suggesting that VCP may play a role in PV replication through cellular secretion pathways (Arita et al., 2012). In addition, other roles for VCP have been described in other picornaviruses (Arita et al., 2012). Although VCP knockdown strongly inhibits PV infection, inhibition of VCP does not affect the replication of Coxsackievirus B3 (Arita et al., 2012), which is also a member of the same genus *Enterovirus*. In contrast, replication of Aichivirus A, genus *Kobuvirus*, another member of family *Picornaviridae*, is enhanced when VCP is depleted (Arita et al., 2012).

A relationship between VCP and Sindbis virus (SINV) replication has also been reported (Panda et al., 2013). VCP is involved in trafficking of the entry receptor of SINV, which is the natural

resistance-associated macrophage protein 2 (NRAMP2). Deficiency of VCP suppresses SINV replication through alteration of trafficking routes of NRAMP2 leading to degradation of NRAMP2 by lysosomes.

Studies of infectious bronchitis virus (IBV), family *Coronaviridae*, have suggested that VCP is engaged in the internalization steps of IBV (Wong et al., 2015). Depletion of VCP using siRNA knockdown, resulted in accumulation of IBV particles in early endosomes as maturation of the endosome and acidification was disrupted. Failure of the acidification of virus-containing endosomes inhibited fusion between the virus envelope and endosomal membrane and prevented IBV exit from the endosomes to the cytosol (Wong et al., 2015)

In the present study, we investigated whether VCP is involved in WNV infection. Specifically, we employed VCP inhibitors and siRNA knockdown to elucidate a potential role of VCP in WNV replication.

2. Methods

2.1 Cell and viruses

Human cervical adenocarcinoma cells, HeLa, were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine. Human embryonic kidney cells, HEK293T, were grown in high glucose DMEM supplemented with 110 mg/L sodium pyruvate, 2 mM L-glutamine and 5% FBS. African green monkey kidney cells, Vero, were grown with Minimum Essential Media (MEM) supplemented with 5% FBS and 2 mM L-glutamine. Human neuroblastoma cells, SK-N-SH, were grown with Minimum Essential Media (MEM) supplemented with 10% FBS and 2 mM L-glutamine. Cells were grown at 37 °C with 5% supplemented CO₂. The mosquito cell line, *Aedes albopictus* clone C6/36, were grown in MEM supplemented with 10% FBS, 1% non-essential amino acid and 2 mM L-glutamine at 28 °C. WNV New York strain (NY99 6-LP) was propagated in C6/36 at 28 °C. WNV-NY99 6-LP was kindly provided by Dr. Takashima (Laboratory of Public Health, Graduate school of Veterinary Medicine,

Hokkaido University, Sapporo, Japan) (Hasebe et al., 2010; Shirato et al., 2004a; Shirato et al., 2004b). Viral titer was measured by plaque assay and stock of viruses were stored at -80 °C until use. All experiments with WNV were performed in the Biosafety level-3 facility at the Research Center for Zoonosis Control, Hokkaido University in accordance with institutional guidelines. Pseudotyped vesicular stomatitis virus (VSV) was provided by Dr. Takada (Research Center for Zoonosis Control, Hokkaido University) (Takada et al., 2007).

2.2 MTT assay

HeLa cells were treated with 5, 10 and 20 µM of Eeyarestatin I (EerI) (Sigma Aldrich, St. Louis, MO) (Wang et al., 2008; Wang et al., 2010) or 12.5, 25 and 50 µM of 3,4-Methylenedioxy-β-nitrostyrene (MDBN) (Abcam, Cambridge, UK) (Chou and Deshaies, 2011) and incubated at 37 °C for 24 h. Thereafter, the treated cells were examined by MTT assay following addition of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and incubated at 37 °C for 1 h, then addition of solubilization solution [10% Triton-X 100 in acidic isopropanol (0.1N HCl)] and incubation at room temperature with shaking for 30 min. Absorbance values were measured at 570 nm and 630 nm using the Model 680 microplate reader (Bio-rad, Hercules, CA).

2.3 Plaque assay

Virus suspensions were diluted in a series of 10-fold dilutions and inoculated onto monolayers of Vero cells. The WNV-inoculated Vero cells were grown with MEM containing 1.25% methyl cellulose, 5% FBS and 2 mM L-glutamine at 37 °C for 4 days. Fixation was done after 4 days using 10% formalin for 10 min at room temperature. The fixed cells were stained with 1% crystal violet in 70% ethanol for 30 min. The number of plaques was counted and the virus titer was determined in plaque forming unit per milliliter (PFU/ml).

2.4 Immunofluorescence assay (IFA)

The WNV-infected cells grown on coverslips were fixed at various times after infection. The infected cells were fixed in 4% paraformaldehyde for 10 min and permeabilized using 0.1% Triton X-100 for 5 min at room temperature. Blocking was performed with 1% bovine serum albumin (BSA) for 30 min before incubation with primary antibody. The cells were incubated with primary antibody (rabbit anti-JEV serum; 1:1,500) (Kimura et al., 1994; Kobayashi et al., 2012) that have cross-reactivity with the WNV antigens at 4 °C overnight, followed by incubation with Alexa Fluor 488-conjugated secondary antibody against rabbit IgG (1:2,000; Life technologies, Rockville, MD) for 1 h at room temperature. The cells were washed three times with phosphate buffered saline (PBS) before fluorescence microscopy examination. The cells were visualized using an inverted fluorescence microscope (IX70, Olympus, Tokyo, Japan) and images were processed using DP manager software (Olympus).

2.5 Immunoblotting analysis

Cell samples were harvested at the indicated time points using TNE lysis buffer [1% Triton X-100, 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 10% glycerol] and centrifuged at 17,800 x g at 4 °C for 20 min. Only supernatants were collected and mixed with SDS-PAGE sample buffer [0.1 M Tris-HCl (pH 6.8), 3.3% SDS, 11% glycerol]. The samples were separated by 8% polyacrylamide gel electrophoresis and then transferred to a polyvinylidene difluoride filter (Merck Millipore, Billerica, MA). The filters were blocked with 5% skimmed milk for 30 min. The filters were incubated with each primary antibody, including mouse anti-VCP antibody (1:2,000; Abcam), mouse anti-envelope protein of West Nile/Kunjin virus (Merck 1:1,000; Millipore), rabbit anti-NS3 serum (1:1,000), which was prepared from a rabbit immunized by twice intravenous inoculations of synthetic peptides of NS3 (CEREKVYTMDGEYRLRGEER), and mouse anti-actin (1:1,000; Merck Millipore). Thereafter, the filters were incubated with secondary antibody, goat anti-mouse IgG antibody conjugated with horseradish peroxidase at 1:10,000 dilution (Biosource International, Camarillo, CA) and washed with TBS [50 mM Tris-HCl (pH 7.5), 150 mM NaCl,] containing

0.05% Tween 20 (TBS-T) three times. Chemiluminescence was detected by Immobilon Western HRP Substrate (Merck Millipore) and visualized with VersaDoc 5000MP (Bio-Rad), and images were analyzed using Quantity One software (Bio-Rad).

2.6 WNV inoculation in the presence of VCP inhibitors

Based on the results of MTT assays, we determined the optimal concentration of EerI (2.5 and 5 μ M) and MDBN (6.25 and 12.5 μ M) without cytotoxicity in HeLa cells. Multiplicity of infection (MOI) of 1 of WNV NY99 6-LP strain was inoculated into HeLa cells. After 1 h of incubation at 37 °C with rocking, the inocula were removed. Suspensions of either EerI or MDBN diluted in normal cultured medium were added to the WNV-inoculated cells and incubated at 37 °C for 24 h. Thereafter, the inoculated-cells and the supernatants were prepared for IFA, plaque assay and immunoblotting analysis to measure the number of WNV-infected cells, production of infectious WNV and expression of WNV proteins, respectively.

2.7 VCP knockdown

The endogenous VCP was inhibited using siRNA. HeLa cells (2×10^4 cells in 250 μ l medium per well) in 48-well plates were transfected with 5 nM of each siRNA targeting VCP, no. (1), (2) and (3), which have the sequences 5'-GAAUAGAGUUGUUCGGAAUTT-3', 5'-GAACCGUCCCAAUCGGUUATT-3', and 5'-GGCUCGUGGAGGUAACAUTT-3' (Thermo Fisher Scientific, Waltham, MA), respectively, using lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) according to the manufacturer's instructions. The transfected cells were incubated at 37 °C for 48 h. The expression level of VCP was evaluated using immunoblotting.

2.8 WNV inoculation in siRNA-treated cells

At 48 h post transfection with either siRNA against VCP or control siRNA (Catalogue No: 439084, Thermo Fisher Scientific), HeLa cells were inoculated with WNV NY99 6-LP strain (MOI=1) and

incubated at 37 °C for 1 h with rotation. Thereafter, supernatants of the cells were removed, and normal HeLa culture medium was added to the cells and incubated at 37 °C for 12, 24 and 48 h. The inoculated cells and the supernatants were prepared for IFA, plaque assay and immunoblotting analysis, respectively. To investigate the role of VCP in the early stages of the WNV replicative cycle, the siRNA-transfected cells were inoculated with WNV as described above. After inoculation of WNV, cells were incubated on ice for 1 h, and then washed with PBS five times. The cells were then placed at 37 °C and incubated for 1 h. Thereafter, the inoculated-cells were harvested using trypsin. The detached cells from cell culture plates were centrifuged at 1,500 x g for 3 min. After removal of supernatants, total RNA was extracted from cell pellets using Trizol (Thermo Fisher Scientific). Extracted total RNAs were analyzed for WNV genome using real-time reverse transcription PCR (qRT-PCR) analysis.

2.9 Pseudotyped VSV inoculation in siRNA-treated cells

It has been previously reported that VCP knockdown did not affect VSV infection (Panda et al., 2013). Therefore, control experiments using pseudotyped VSV were performed. The pseudotyped VSV encoding GFP was kindly provided by Dr. Takada (Hokkaido University) (Takada et al., 2007). Approximately 30% infectivity of pseudotyped VSV was inoculated into HeLa cells transfected with either siRNA against VCP or control siRNA. The cells were incubated at 37 °C with rotation for 1 h. Thereafter, supernatants of the cells were removed, normal growth media was added to the cells and incubated at 37 °C for 8 h. The percentage positivity following pseudotyped VSV infection was measured by counting the number of GFP-positive cells using an inverted fluorescence microscope (IX70, Olympus, Tokyo, Japan).

2.10 Production of WNV virus-like particles (WNV-VLPs)

WNV-VLPs with reporter DsRed protein were produced following transfection. Three plasmid vectors carrying WNV sequences: pCMV-WNrep-DsRed, pCMV-SVP and pCSXN-C were

transfected into HEK293T cells using lipofectamine 2000 (Thermo Fisher Scientific). These plasmids were constructed as follows. A plasmid encoding WNV replicon cDNA, pCMV-WNrep-DsRed encodes the WNV non-structural (NS1-NS5) proteins. Almost all of the sequences encoding structural proteins, including C, prM and E, were deleted and replaced by the gene encoding the DsRed protein. The 3'-terminus of the WNV genome was accomplished by containing sequences enabling ribozyme-mediated post-transcriptional cleavage of the RNA (Kobayashi et al., 2016b). The fragment of prM-E was amplified by PCR from pCAGGS-C-prM-E, which was a gift from Dr. Takashima (Hokkaido University) (Takahashi et al., 2009) as a template, and subcloned into the pCMV vector, and the plasmid was named pCMV-SVP. For the pCSXN-C, the C fragment with restriction sequences of Xho I and Not I (Takara Bio, Kyoto, Japan) were amplified by PCR and inserted into pCSXN-flag which was generated from pCMV-myc (Clontech Laboratories, Mountain View, CA) as previously described (Kobayashi et al., 2013), using Xho I and Not I restriction sites. The plasmid was named as pCXSXN-C. The transfected cells were incubated at 37 °C for 72 h. The supernatants from transfected cells were collected and filtered through a 0.45 µm filter (Sigma Aldrich). The WNV-VLPs were concentrated by ultracentrifugation at 4 °C, 68,000 x g for 2 h. The supernatant was discarded and only the pellet was collected after ultracentrifugation. The pellet was resuspended with normal HeLa culture medium and the titers of WNV-VLPs were measured by hemagglutination assay as previously described (Makino et al., 2014). The titer of VLPs was calculated as hemagglutination units (HAU)/50 µl based on the highest dilution of VLP suspension causing agglutination of chicken red blood cells.

2.11 Inoculation of WNV-VLPs in VCP knockdown HeLa cells

WNV-VLPs (16 HAU/50 µl) were inoculated into siRNA-treated HeLa cells 48 h post transfection. After 1 h incubation at 37 °C, the inocula were discarded and normal HeLa culture medium was added and incubated for 72 h. Comparison of the quantity of WNV-RNA between VCP knockdown and control was determined using qRT-PCR.

286

287 **2.12 WNV-VLP production and transfection of pCMV-WNrep-DsRed to siRNA-treated**

288 **HeLa cells**

289 Plasmid transfection to generate WNV-VLPs has been reported to investigate the role of VCP in the
290 late steps of viral life cycle, from genome replication to virus release (Kobayashi et al., 2016a). The
291 results obtained employing the plasmid-encoded VLPs would not be attributable to early steps of
292 WNV infection, including attachment and entry. WNV-VLPs were used to investigate the role of
293 VCP in distinct steps (early and genome replication steps) of WNV infection cycle. At 24 h after
294 siRNA transfection, the plasmid set (pCMV-WNrep-DsRed, pCMV-SVP and pCSXN-C) was
295 transfected into siRNA-treated HeLa cells using FuGENE HD (Promega, Madison, WI). The
296 plasmid transfected-cells were incubated at 37 °C for 72 h. Thereafter, the supernatants from
297 transfected cells were collected and inoculated onto Vero cells monolayers in 10-fold serial
298 dilutions. WNV-VLP titer was calculated as infectious units (IFU)/ml based on the total number of
299 DsRed-positive cells (Figure 3C).

300 To investigate the role of VCP in WNV genomic RNA replication, only pCMV-WNrep-DsRed
301 (Kobayashi et al., 2016b) was transfected into the siRNA-treated cells. The procedure and time of
302 transfection are similar to plasmid transfection for VLP production. After 72 h incubation, the total
303 RNAs were extracted and prepared for qRT-PCR.

304

305 **2.13 Real-time reverse transcription-PCR (qRT-PCR)**

306 Total RNA was isolated by Trizol and chloroform according to the manufacturer's protocol. The
307 RNA samples were treated with DNase I (Thermo Fisher Scientific) to remove genomic DNA.

308 qRT-PCR was performed with a Brilliant III Ultra-Fast qRT-PCR master mix (Agilent
309 Technologies, Santa Clara, CA) following the manufacturer's protocol. The oligonucleotide primers
310 and fluorescent probe targeting the 3'UTR of WNV, 5'-AAGTTGAGTAGACGGTGCTG-3' and 5'-
311 AGACGGTTCTGAGGGCTTAC-3', WNV probe, FAM-5'-GCTCAACCCCAGGAGGACTGG-3'-

BHQ, were used for detection of WNV-RNA. A TaqMan Gene expression assays kit corresponding to human β -actin (Thermo Fisher Scientific) was used as an endogenous control. The expression level of viral RNA was normalized to the expression of human β -actin.

2.14 Statistical analysis

The statistical significance was calculated using one-way ANOVA.

3. Results

3.1 WNV infection is inhibited in the presence of VCP inhibitors.

To determine if VCP is involved in WNV infection, the effect of VCP inhibitors, both EerI (Wang et al., 2008; Wang et al., 2010) and MDBN (Chou and Deshaies, 2011) at concentrations without cytotoxicity were assayed in WNV infection. The cytotoxicity of either EerI or MDBN treatment in HeLa cells was examined using a MTT assay (Supplementary Fig. 1). Each VCP inhibitor was added to HeLa cells at 1 h.p.i. with WNV. WNV-inoculated cells and cultured supernatants were harvested at 24 h.p.i. The number of WNV-infected cells was examined by IFA, and this revealed that the number of WNV-infected cells was significantly decreased in a dose-dependent manner in the presence of either EerI or MDBN (Fig. 1A and 1B). Viral titers of supernatants from WNV-inoculated cells were also measured by plaque assay. Consistently, this demonstrated that viral titers of supernatants from WNV-inoculated cells were significantly decreased in a dose-dependent manner in the presence of either EerI or MDBN (Fig. 1C). We also confirmed the inhibitory effects of EerI in WNV infection in a different cell line, human neuroblastoma SK-N-SH cells. Inhibition of VCP by EerI both decreased the percentage of WNV-infected cells and viral titer in SK-N-SH cells (Supplementary Fig. 2). These findings suggest that VCP may play a role in WNV infection.

3.2 WNV infection is inhibited by knockdown of VCP

To confirm that the inhibition of WNV infection was caused by perturbation of VCP activity, small interfering RNAs (siRNAs) were employed to deplete endogenous VCP. HeLa cells were transfected with either of three siRNAs targeting three different regions of the VCP gene [siVCP (1), (2) and (3)] or a control siRNA (siCont) and then inoculated with WNV 48 h post transfection and incubated for 24 h. The expression level of VCP after silencing was confirmed by immunoblotting. Reverse transfection of siVCP (1) and (3) for 48 h strongly decreased expression levels of endogenous VCP in HeLa cells (Fig. 2A). Furthermore, depletion of endogenous VCP reduced expression levels of WNV-E protein at 24 h.p.i. of WNV (Fig. 2A). Thereafter, we examined siRNA targeting of VCP [(1) and (3)] which significantly reduced the percentage of WNV-infected cells (Fig. 2B and 2C). However, siRNA (2) failed to knockdown endogenous VCP as shown in the immunoblotting and IFA results (Fig. 2A, 2B and 2C). We further measured viral titers in supernatants of WNV-inoculated HeLa cells treated by the siRNAs against VCP. Plaque assays revealed that the viral release was significantly inhibited by siRNA treatment [siVCP (1) and (3)] (Fig. 2D). We also examined the effect of siRNA against VCP on WNV infection by IFA at different time points (12, 24 and 48 h). A decrease in the immunofluorescence signals between cells transfected with control and VCP siRNAs was detected (Supplementary Fig. 3). These results indicate that a depletion of VCP significantly inhibits WNV infection. In contrast, VCP-knockdown did not affect infection by pseudotyped VSV (Supplementary Fig. 4).

3.3 VCP participates in the early and genome replication steps during the WNV life cycle

We next investigated the specific role of VCP in the life cycle of WNV. The intracellular life cycle of WNV is divided into two major steps, early and late (Fernandez-Garcia et al., 2011; Kaufmann and Rossmann, 2011). The early step consists of viral attachment, entry and uncoating (Jiang et al., 2010; Kaufmann and Rossmann, 2011), while the late step involves genome translation, genome replication, viral assembly and release (Kobayashi et al., 2016a). WNV-VLPs were employed to determine whether VCP participates in the early or late replication steps (Kobayashi et al., 2014).

WNV-VLPs are unable to produce progeny virions because of the absence of WNV structural protein coding sequences in their genome. Therefore, our results are independent of the assembly and virion-releasing steps (Hasebe et al., 2010; Scholle et al., 2004). Thus, WNV- VLPs allow the determination of whether VCP plays a role in either an early step or during the genomic replication of the WNV life cycle. WNV-VLPs were inoculated into both VCP and control siRNA-transfected cells and monitored by expression of DsRed-encoded in the WNV-VLP replicon. qRT-PCR demonstrated that the quantity of WNV-RNA in VCP-knockdown (siVCP (1)) cells was significantly lower than that in control siRNA-treated cells (Fig. 3A). These results suggest that VCP knockdown significantly inhibits infection of WNV-VLPs through an inhibition of early step and/or genome replication steps of the WNV life cycle.

To confirm the role of VCP in the early stages of WNV replication, the siRNA-treated cells were inoculated with WNV and viral RNA was investigated at an early time point of WNV infection, at 2 h post infection. The result revealed that silencing of VCP (siVCP (1)) significantly decreased the quantity of WNV-RNA at 2 h post inoculation of WNV compared to control siRNA treated-cells (Fig. 3B). This suggests that VCP plays a role in the early step of WNV replication cycle, including attachment or entry into cells.

To examine whether VCP plays a role in the late step of the WNV life cycle, three plasmids encoding WNV sequences (pCMV-C, pCMV-SVP and pCMV-WNrep-DsRed) were co-transfected into either VCP-knockdown (siVCP (1)) or control siRNA-treated cells. The plasmid transfection protocol for VLP production has been previously employed to investigate the role of host factor(s) in the late stages of viral infection, including genome replication and virus release (Kobayashi et al., 2016a). The components of the VLP are transfected into cells, therefore, the results obtained employing the plasmid-encoded VLPs were not associated with the early steps of WNV replication (Kobayashi et al., 2016a). At 72 h after plasmid transfection, we examined the WNV-VLP titers in the supernatants from plasmid transfected-cells. The titer of WNV-VLPs was significantly decreased in VCP-knockdown (siVCP (1)) cells compared with control siRNA-treated cells (Fig.

3C). These data suggest that VCP is also involved in the genome replication and/or assembly and release steps of the WNV life cycle.

To confirm that VCP is important for WNV genome replication, the WNV DNA-based replicon pCMV-WNrep-DsRed was introduced into both VCP knockdown and control siRNA-treated cells. This replicon consists of coding sequences of WNV non-structural proteins, while almost all of the sequences encoding WNV structural proteins were deleted and replaced by sequences encoding DsRed. The replicon can replicate and translate to synthesize viral genomic RNA and the non-structural proteins of WNV, respectively. However, it is not capable of producing viral progeny because of the absence of structural protein sequences of WNV. The results of qRT-PCR of the plasmid-transfected cells at 72 h post transfection demonstrated a 10-fold reduction of synthesized WNV-RNA in the VCP-knockdown cells (siVCP (1)) compared to control siRNA-treated cells (Fig. 3D). Taken together, these data indicate that VCP plays a role in the genome replication of the WNV life cycle.

4. Discussion

In the present study, we have investigated the roles of VCP during WNV infection. We found that perturbation of endogenous VCP using a potent VCP inhibitor or siRNA targeting VCP significantly inhibited WNV infection. We could confirm that the expression of endogenous VCP in HeLa cells is depleted after 48 h siRNA transfection [with siVCP (1) and (3)], while another siRNA siVCP (2) did not silence expression of endogenous VCP. Silencing of endogenous VCP, by siVCP (1) and (3), demonstrated that depletion of VCP significantly suppressed WNV infection. This finding suggests that VCP is required for WNV infection and, thereafter, we employed the most potent siRNA [siVCP (1)] to investigate the roles of VCP in WNV replication. A previous report indicated that silencing of endogenous VCP and nuclear protein localization 4 (NPL4), a VCP cofactor, did not inhibit WNV infection, whereas depletion of ubiquitin fusion degradation 1-like (UFD1L) and p47, other cofactors of VCP, suppressed WNV infection (Krishnan et al., 2008). We

suggest that the differences between this previous report and the present results may be related to the use of different strains of WNV or could be related to the silencing efficiency of the siRNA employed in the experiments. In addition, control experiments from the present study using pseudotyped VSV demonstrated that depletion of VCP did not suppress pseudotyped VSV infection. These results suggest that VCP plays a role in WNV infection specifically and inhibition of WNV infection in VCP knockdown cells is not a consequence of cellular cytotoxicity.

Employing VLPs, we demonstrated that perturbation of VCP suppressed the infectivity of WNV-VLPs (Fig. 3A). This indicates that VCP is potentially involved in either the early steps or during genome replication of WNV. Using plasmid transfection to generate WNV-VLPs, to bypass early steps of the WNV life cycle, we next examined whether VCP plays a role in the late steps (from genome replication until virus release) of the viral life cycle. Knockdown of VCP reduced the yield of WNV-VLPs compared to control siRNA-treated cells (Fig. 3C) and this finding suggests that VCP also participates in the late steps of WNV life cycle. Taken together, we hypothesized that VCP may be implicated in the genome replication steps of WNV. Therefore, a WNV DNA-based replicon was employed to clarify whether VCP is required for genome replication of WNV. Depletion of VCP significantly decreased expression levels of synthesized WNV-RNA (Fig. 3D) and this finding indicates that VCP is engaged in WNV genomic RNA replication.

It has been previously reported that VCP was found to be localized in the cytosol, ER and nucleus, and can play a role in several cellular processes (Arita et al., 2012; Meyer et al., 2012; Meyer and Wehl, 2014; Yamanaka et al., 2012). The possible mechanism(s) of VCP involvement in WNV infection may be based on the localization and physiological function of VCP. Functional roles of VCP in the replication of the WNV-related virus in the family *Flaviviridae*, hepatitis C virus (HCV) have been reported (Yi et al., 2016). VCP knockdown significantly decreased expression of HCV RNA levels and VCP was found to be colocalized with the HCV replication complex. It is thus possible that this function of VCP in the HCV life cycle is also required for

WNV genome replication, however, no direct evidence currently exists for an interaction between WNV replicase components and VCP and further investigations are required.

Apart from during the genome replication of the WNV life cycle, VCP might potentially be involved in other steps. The present study demonstrates that VCP may also function in the early steps, during either attachment or entry, of the viral life cycle (Fig. 3B). The results of an entry assay revealed that silencing of endogenous VCP caused a significant reduction in the expression levels of WNV-RNA compared to control siRNA-treated cells. This suggests that VCP may also play a role in either the binding or entry steps of the WNV life cycle. A role for VCP in early stages of viral infection has previously been reported for coronavirus and Sindbis virus (Panda et al., 2013; Wong et al., 2015). Depletion of VCP inhibited coronavirus infection through a failure in the maturation of virus-loaded endosomes leading to accumulation of coronavirus particles in the early endosomal compartment (Wong et al., 2015). Studies on Sindbis virus indicated that VCP functioned as a regulator of viral entry as knockdown of VCP caused an alteration of trafficking and resulted in the degradation of Sindbis virus entry receptor (Panda et al., 2013). However, the possible function of VCP on early stages of WNV replication has not been investigated and will require further study.

In conclusion, our findings suggest that VCP is required for replication of WNV at a number of different stages of the viral life cycle, thus, VCP potentially represents a candidate for the therapeutic inhibition of WNV infection.

Reference

- Ambrose, R.L., Mackenzie, J.M., 2011. West Nile virus differentially modulates the unfolded protein response to facilitate replication and immune evasion. *J Virol* 85(6), 2723-2732.
- Arita, M., Wakita, T., Shimizu, H., 2012. Valosin-containing protein (VCP/p97) is required for poliovirus replication and is involved in cellular protein secretion pathway in poliovirus infection. *J Virol* 86(10), 5541-5553.

466 Bogachek, M.V., Zaitsev, B.N., Sekatskii, S.K., Protopopova, E.V., Ternovoi, V.A., Ivanova, A.V.,
 467 Kachko, A.V., Ivanisenko, V.A., Dietler, G., Loktev, V.B., 2010. Characterization of
 468 glycoprotein E C-end of West Nile virus and evaluation of its interaction force with
 469 alphaVbeta3 integrin as putative cellular receptor. *Biochemistry (Mosc)* 75(4), 472-480.
 470 Brinton, M.A., 2014. Replication cycle and molecular biology of the West Nile virus. *Viruses* 6(1),
 471 13-53.
 472 Buchan, J.R., Kolaitis, R.M., Taylor, J.P., Parker, R., 2013. Eukaryotic stress granules are cleared
 473 by autophagy and Cdc48/VCP function. *Cell* 153(7), 1461-1474.
 474 Bug, M., Meyer, H., 2012. Expanding into new markets--VCP/p97 in endocytosis and autophagy. *J*
 475 *Struct Biol* 179(2), 78-82.
 476 C., S.K., P., H.T., W., B.A., J., P.H., 1940. A Neurotropic Virus Isolated from the Blood of a Native
 477 of Uganda. *s1-20(20)*, 471-492.
 478 Carnec, X., Meertens, L., Dejarnac, O., Perera-Lecoin, M., Hafirassou, M.L., Kitaura, J., Ramdasi,
 479 R., Schwartz, O., Amara, A., 2016. The Phosphatidylserine and Phosphatidylethanolamine
 480 Receptor CD300a Binds Dengue Virus and Enhances Infection. *J Virol* 90(1), 92-102.
 481 Chahar, H.S., Chen, S., Manjunath, N., 2013. P-body components LSM1, GW182, DDX3, DDX6
 482 and XRN1 are recruited to WNV replication sites and positively regulate viral replication.
 483 *Virology* 436(1), 1-7.
 484 Chou, T.F., Deshaies, R.J., 2011. Quantitative cell-based protein degradation assays to identify and
 485 classify drugs that target the ubiquitin-proteasome system. *J Biol Chem* 286(19), 16546-
 486 16554.
 487 Chu, J.J., Leong, P.W., Ng, M.L., 2006. Analysis of the endocytic pathway mediating the infectious
 488 entry of mosquito-borne flavivirus West Nile into *Aedes albopictus* mosquito (C6/36) cells.
 489 *Virology* 349(2), 463-475.
 490 Chu, J.J., Ng, M.L., 2004. Infectious entry of West Nile virus occurs through a clathrin-mediated
 491 endocytic pathway. *J Virol* 78(19), 10543-10555.

492 Courtney, S.C., Scherbik, S.V., Stockman, B.M., Brinton, M.A., 2012. West Nile virus infections
 493 suppress early viral RNA synthesis and avoid inducing the cell stress granule response. *J*
 494 *Virol* 86(7), 3647-3657.

495 Dargemont, C., Ossareh-Nazari, B., 2012. Cdc48/p97, a key actor in the interplay between
 496 autophagy and ubiquitin/proteasome catabolic pathways. *Biochim Biophys Acta* 1823(1),
 497 138-144.

498 Dauphin, G., Zientara, S., Zeller, H., Murgue, B., 2004. West Nile: worldwide current situation in
 499 animals and humans. *Comp Immunol Microbiol Infect Dis* 27(5), 343-355.

500 Davis, C.W., Nguyen, H.Y., Hanna, S.L., Sánchez, M.D., Doms, R.W., Pierson, T.C., 2006. West
 501 Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and
 502 infection. *J Virol* 80(3), 1290-1301.

503 Denizot, M., Neal, J.W., Gasque, P., 2012. Encephalitis due to emerging viruses: CNS innate
 504 immunity and potential therapeutic targets. *J Infect* 65(1), 1-16.

505 Egberink, H., Addie, D.D., Boucraut-Baralon, C., Frymus, T., Gruffydd-Jones, T., Hartmann, K.,
 506 Horzinek, M.C., Hosie, M.J., Marsilio, F., Lloret, A., Lutz, H., Pennisi, M.G., Radford,
 507 A.D., Thiry, E., Truyen, U., Möstl, K., Diseases, E.A.B.o.C., 2015. West Nile virus
 508 infection in cats: ABCD guidelines on prevention and management. *J Feline Med Surg*
 509 17(7), 617-619.

510 Fernandez-Garcia, M.D., Meertens, L., Bonazzi, M., Cossart, P., Arenzana-Seisdedos, F., Amara,
 511 A., 2011. Appraising the roles of CBLL1 and the ubiquitin/proteasome system for flavivirus
 512 entry and replication. *J Virol* 85(6), 2980-2989.

513 Fields, B.N., Knipe, D.M., Howley, P.M., 2013. *Fields virology*. 6th ed. 2 vols. Wolters Kluwer
 514 Health/Lippincott Williams & Wilkins, Philadelphia.

515 Gamino, V., Escribano-Romero, E., Blázquez, A.B., Gutiérrez-Guzmán, A.V., Martín-Acebes, M.,
 516 Saiz, J.C., Höfle, U., 2016. Experimental North American West Nile Virus Infection in the
 517 Red-legged Partridge (*Alectoris rufa*). *Vet Pathol* 53(3), 585-593.

518 Gilfoy, F., Fayzulin, R., Mason, P.W., 2009. West Nile virus genome amplification requires the
 519 functional activities of the proteasome. *Virology* 385(1), 74-84.

520 Gillespie, L.K., Hoenen, A., Morgan, G., Mackenzie, J.M., 2010. The endoplasmic reticulum
 521 provides the membrane platform for biogenesis of the flavivirus replication complex. *J Virol*
 522 84(20), 10438-10447.

523 Hasebe, R., Suzuki, T., Makino, Y., Igarashi, M., Yamanouchi, S., Maeda, A., Horiuchi, M., Sawa,
 524 H., Kimura, T., 2010. Transcellular transport of West Nile virus-like particles across human
 525 endothelial cells depends on residues 156 and 159 of envelope protein. *BMC Microbiol* 10,
 526 165.

527 Heinz, F.X., Allison, S.L., 2000. Structures and mechanisms in flavivirus fusion. *Adv Virus Res* 55,
 528 231-269.

529 Jiang, D., Weidner, J.M., Qing, M., Pan, X.B., Guo, H., Xu, C., Zhang, X., Birk, A., Chang, J., Shi,
 530 P.Y., Block, T.M., Guo, J.T., 2010. Identification of five interferon-induced cellular proteins
 531 that inhibit west nile virus and dengue virus infections. *J Virol* 84(16), 8332-8341.

532 Kaufmann, B., Rossmann, M.G., 2011. Molecular mechanisms involved in the early steps of
 533 flavivirus cell entry. *Microbes Infect* 13(1), 1-9.

534 Kaufusi, P.H., Kelley, J.F., Yanagihara, R., Nerurkar, V.R., 2014. Induction of endoplasmic
 535 reticulum-derived replication-competent membrane structures by West Nile virus non-
 536 structural protein 4B. *PLoS One* 9(1), e84040.

537 Kimura, T., Kimura-Kuroda, J., Nagashima, K., Yasui, K., 1994. Analysis of virus-cell binding
 538 characteristics on the determination of Japanese encephalitis virus susceptibility. *Arch Virol*
 539 139(3-4), 239-251.

540 Kobayashi, S., Orba, Y., Yamaguchi, H., Kimura, T., Sawa, H., 2012. Accumulation of
 541 ubiquitinated proteins is related to West Nile virus-induced neuronal apoptosis.
 542 *Neuropathology* 32(4), 398-405.

543 Kobayashi, S., Orba, Y., Yamaguchi, H., Takahashi, K., Sasaki, M., Hasebe, R., Kimura, T., Sawa,
 544 H., 2014. Autophagy inhibits viral genome replication and gene expression stages in West
 545 Nile virus infection. *Virus Res* 191, 83-91.

546 Kobayashi, S., Suzuki, T., Igarashi, M., Orba, Y., Ohtake, N., Nagakawa, K., Niikura, K., Kimura,
 547 T., Kasamatsu, H., Sawa, H., 2013. Cysteine residues in the major capsid protein, Vp1, of
 548 the JC virus are important for protein stability and oligomer formation. *PLoS One* 8(10),
 549 e76668.

550 Kobayashi, S., Suzuki, T., Kawaguchi, A., Phongphaew, W., Yoshii, K., Iwano, T., Harada, A.,
 551 Kariwa, H., Orba, Y., Sawa, H., 2016a. Rab8b Regulates Transport of West Nile Virus
 552 Particles from Recycling Endosomes. *J Biol Chem* 291(12), 6559-6568.

553 Kobayashi, S., Yoshii, K., Hirano, M., Muto, M., Kariwa, H., 2016b. A Novel Reverse Genetics
 554 System for Production of Infectious West Nile Virus using Homologous Recombination in
 555 Mammalian Cells. *J Virol Methods*.

556 Koller, K.J., Brownstein, M.J., 1987. Use of a cDNA clone to identify a supposed precursor protein
 557 containing valosin. *Nature* 325(6104), 542-545.

558 Kramer, L.D., Bernard, K.A., 2001. West Nile virus infection in birds and mammals. *Ann N Y*
 559 *Acad Sci* 951, 84-93.

560 Krishnan, M.N., Ng, A., Sukumaran, B., Gilfoy, F.D., Uchil, P.D., Sultana, H., Brass, A.L.,
 561 Adametz, R., Tsui, M., Qian, F., Montgomery, R.R., Lev, S., Mason, P.W., Koski, R.A.,
 562 Elledge, S.J., Xavier, R.J., Agaisse, H., Fikrig, E., 2008. RNA interference screen for human
 563 genes associated with West Nile virus infection. *Nature* 455(7210), 242-245.

564 Lichtensteiger, C.A., Heinz-Taheny, K., Osborne, T.S., Novak, R.J., Lewis, B.A., Firth, M.L., 2003.
 565 West Nile virus encephalitis and myocarditis in wolf and dog. *Emerg Infect Dis* 9(10),
 566 1303-1306.

567 Ma, H., Dang, Y., Wu, Y., Jia, G., Anaya, E., Zhang, J., Abraham, S., Choi, J.G., Shi, G., Qi, L.,
 568 Manjunath, N., Wu, H., 2015. A CRISPR-Based Screen Identifies Genes Essential for West-
 569 Nile-Virus-Induced Cell Death. *Cell Rep* 12(4), 673-683.

570 Makino, Y., Suzuki, T., Hasebe, R., Kimura, T., Maeda, A., Takahashi, H., Sawa, H., 2014.
 571 Establishment of tracking system for West Nile virus entry and evidence of microtubule
 572 involvement in particle transport. *J Virol Methods* 195, 250-257.

573 Maric, M., Maculins, T., De Piccoli, G., Labib, K., 2014. Cdc48 and a ubiquitin ligase drive
 574 disassembly of the CMG helicase at the end of DNA replication. *Science* 346(6208),
 575 1253596.

576 Martina, B.E., Koraka, P., van den Doel, P., Rimmelzwaan, G.F., Haagmans, B.L., Osterhaus, A.D.,
 577 2008. DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and
 578 virus replication in human dendritic cells induces production of IFN-alpha and TNF-alpha.
 579 *Virus Res* 135(1), 64-71.

580 Meyer, H., Bug, M., Bremer, S., 2012. Emerging functions of the VCP/p97 AAA-ATPase in the
 581 ubiquitin system. *Nat Cell Biol* 14(2), 117-123.

582 Meyer, H., Wehl, C.C., 2014. The VCP/p97 system at a glance: connecting cellular function to
 583 disease pathogenesis. *J Cell Sci* 127(Pt 18), 3877-3883.

584 Morizono, K., Chen, I.S., 2014. Role of phosphatidylserine receptors in enveloped virus infection. *J*
 585 *Virol* 88(8), 4275-4290.

586 Panda, D., Rose, P.P., Hanna, S.L., Gold, B., Hopkins, K.C., Lyde, R.B., Marks, M.S., Cherry, S.,
 587 2013. Genome-wide RNAi screen identifies SEC61A and VCP as conserved regulators of
 588 Sindbis virus entry. *Cell Rep* 5(6), 1737-1748.

589 Paz, S., 2015. Climate change impacts on West Nile virus transmission in a global context. *Philos*
 590 *Trans R Soc Lond B Biol Sci* 370(1665).

591 Perera-Lecoin, M., Meertens, L., Carnec, X., Amara, A., 2014. Flavivirus entry receptors: an
 592 update. *Viruses* 6(1), 69-88.

593 Plevka, P., Battisti, A.J., Sheng, J., Rossmann, M.G., 2014. Mechanism for maturation-related
 594 reorganization of flavivirus glycoproteins. *J Struct Biol* 185(1), 27-31.
 595 Pye, V.E., Dreveny, I., Briggs, L.C., Sands, C., Beuron, F., Zhang, X., Freemont, P.S., 2006. Going
 596 through the motions: the ATPase cycle of p97. *J Struct Biol* 156(1), 12-28.
 597 Ramanathan, H.N., Ye, Y., 2012. The p97 ATPase associates with EEA1 to regulate the size of
 598 early endosomes. *Cell Res* 22(2), 346-359.
 599 Read, R.W., Rodriguez, D.B., Summers, B.A., 2005. West Nile virus encephalitis in a dog. *Vet*
 600 *Pathol* 42(2), 219-222.
 601 Ritz, D., Vuk, M., Kirchner, P., Bug, M., Schütz, S., Hayer, A., Bremer, S., Lusk, C., Baloh, R.H.,
 602 Lee, H., Glatter, T., Gstaiger, M., Aebersold, R., Wehl, C.C., Meyer, H., 2011.
 603 Endolysosomal sorting of ubiquitylated caveolin-1 is regulated by VCP and UBXD1 and
 604 impaired by VCP disease mutations. *Nat Cell Biol* 13(9), 1116-1123.
 605 Roby, J.A., Setoh, Y.X., Hall, R.A., Khromykh, A.A., 2015. Post-translational regulation and
 606 modifications of flavivirus structural proteins. *J Gen Virol* 96(Pt 7), 1551-1569.
 607 Samuel, M.A., Diamond, M.S., 2006. Pathogenesis of West Nile Virus infection: a balance between
 608 virulence, innate and adaptive immunity, and viral evasion. *J Virol* 80(19), 9349-9360.
 609 Scholle, F., Girard, Y.A., Zhao, Q., Higgs, S., Mason, P.W., 2004. trans-Packaged West Nile virus-
 610 like particles: infectious properties in vitro and in infected mosquito vectors. *J Virol* 78(21),
 611 11605-11614.
 612 Seguin, S.J., Morelli, F.F., Vinet, J., Amore, D., De Biasi, S., Poletti, A., Rubinsztein, D.C., Carra,
 613 S., 2014. Inhibition of autophagy, lysosome and VCP function impairs stress granule
 614 assembly. *Cell Death Differ* 21(12), 1838-1851.
 615 Shimojima, M., Takenouchi, A., Shimoda, H., Kimura, N., Maeda, K., 2014. Distinct usage of three
 616 C-type lectins by Japanese encephalitis virus: DC-SIGN, DC-SIGNR, and LSECtin. *Arch*
 617 *Virol* 159(8), 2023-2031.

618 Shirato, K., Kimura, T., Mizutani, T., Kariwa, H., Takashima, I., 2004a. Different chemokine
 619 expression in lethal and non-lethal murine West Nile virus infection. *J Med Virol* 74(3),
 620 507-513.

621 Shirato, K., Miyoshi, H., Goto, A., Ako, Y., Ueki, T., Kariwa, H., Takashima, I., 2004b. Viral
 622 envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the
 623 New York strain of West Nile virus. *J Gen Virol* 85(Pt 12), 3637-3645.

624 Smit, J.M., Moesker, B., Rodenhuis-Zybert, I., Wilschut, J., 2011. Flavivirus cell entry and
 625 membrane fusion. *Viruses* 3(2), 160-171.

626 Stolz, A., Hilt, W., Buchberger, A., Wolf, D.H., 2011. Cdc48: a power machine in protein
 627 degradation. *Trends Biochem Sci* 36(10), 515-523.

628 Suthar, M.S., Diamond, M.S., Gale, M., 2013. West Nile virus infection and immunity. *Nat Rev*
 629 *Microbiol* 11(2), 115-128.

630 Takada, A., Ebihara, H., Feldmann, H., Geisbert, T.W., Kawaoka, Y., 2007. Epitopes required for
 631 antibody-dependent enhancement of Ebola virus infection. *J Infect Dis* 196 Suppl 2, S347-
 632 356.

633 Takahashi, H., Ohtaki, N., Maeda-Sato, M., Tanaka, M., Tanaka, K., Sawa, H., Ishikawa, T.,
 634 Takamizawa, A., Takasaki, T., Hasegawa, H., Sata, T., Hall, W.W., Kurata, T., Kojima, A.,
 635 2009. Effects of the number of amino acid residues in the signal segment upstream or
 636 downstream of the NS2B-3 cleavage site on production and secretion of prM/M-E virus-like
 637 particles of West Nile virus. *Microbes Infect* 11(13), 1019-1028.

638 Troupin, A., Colpitts, T.M., 2016. Overview of West Nile Virus Transmission and Epidemiology.
 639 *Methods Mol Biol* 1435, 15-18.

640 Verma, R., Oania, R., Fang, R., Smith, G.T., Deshaies, R.J., 2011. Cdc48/p97 mediates UV-
 641 dependent turnover of RNA Pol II. *Mol Cell* 41(1), 82-92.

642 Wang, Q., Li, L., Ye, Y., 2008. Inhibition of p97-dependent protein degradation by Eeyarestatin I. *J*
 643 *Biol Chem* 283(12), 7445-7454.

644 Wang, Q., Shinkre, B.A., Lee, J.G., Weniger, M.A., Liu, Y., Chen, W., Wiestner, A., Trenkle,
 645 W.C., Ye, Y., 2010. The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a
 646 membrane-binding domain and a p97/VCP inhibitory group. *PLoS One* 5(11), e15479.
 647 Welsch, S., Miller, S., Romero-Brey, I., Merz, A., Bleck, C.K., Walther, P., Fuller, S.D., Antony,
 648 C., Krijnse-Locker, J., Bartenschlager, R., 2009. Composition and three-dimensional
 649 architecture of the dengue virus replication and assembly sites. *Cell Host Microbe* 5(4), 365-
 650 375.
 651 Wilcox, A.J., Laney, J.D., 2009. A ubiquitin-selective AAA-ATPase mediates transcriptional
 652 switching by remodelling a repressor-promoter DNA complex. *Nat Cell Biol* 11(12), 1481-
 653 1486.
 654 Wolf, D.H., Stolz, A., 2012. The Cdc48 machine in endoplasmic reticulum associated protein
 655 degradation. *Biochim Biophys Acta* 1823(1), 117-124.
 656 Wong, H.H., Kumar, P., Tay, F.P., Moreau, D., Liu, D.X., Bard, F., 2015. Genome-Wide Screen
 657 Reveals Valosin-Containing Protein Requirement for Coronavirus Exit from Endosomes. *J*
 658 *Virol* 89(21), 11116-11128.
 659 Xia, D., Tang, W.K., Ye, Y., 2016. Structure and function of the AAA+ ATPase p97/Cdc48p. *Gene*
 660 583(1), 64-77.
 661 Yamanaka, K., Sasagawa, Y., Ogura, T., 2012. Recent advances in p97/VCP/Cdc48 cellular
 662 functions. *Biochim Biophys Acta* 1823(1), 130-137.
 663 Yi, Z., Fang, C., Zou, J., Xu, J., Song, W., Du, X., Pan, T., Lu, H., Yuan, Z., 2016. Affinity
 664 Purification of the Hepatitis C Virus Replicase Identifies Valosin-Containing Protein, a
 665 Member of the ATPases Associated with Diverse Cellular Activities Family, as an Active
 666 Virus Replication Modulator. *J Virol* 90(21), 9953-9966.
 667 Yu, I.M., Zhang, W., Holdaway, H.A., Li, L., Kostyuchenko, V.A., Chipman, P.R., Kuhn, R.J.,
 668 Rossmann, M.G., Chen, J., 2008. Structure of the immature dengue virus at low pH primes
 669 proteolytic maturation. *Science* 319(5871), 1834-1837.

Zaitsev, B.N., Benedetti, F., Mikhaylov, A.G., Korneev, D.V., Sekatskii, S.K., Karakouz, T.,
 Belavin, P.A., Netesova, N.A., Protopopova, E.V., Konovalova, S.N., Dietler, G., Loktev,
 V.B., 2014. Force-induced globule-coil transition in laminin binding protein and its role for
 viral-cell membrane fusion. *J Mol Recognit* 27(12), 727-738.

Zhong, X., Pittman, R.N., 2006. Ataxin-3 binds VCP/p97 and regulates retrotranslocation of ERAD
 substrates. *Hum Mol Genet* 15(16), 2409-2420.

Zidane, N., Ould-Abeih, M.B., Petit-Topin, I., Bedouelle, H., 2013. The folded and disordered
 domains of human ribosomal protein SA have both idiosyncratic and shared functions as
 membrane receptors. *Biosci Rep* 33(1), 113-124.

Centers for Disease Control and Prevention (CDC), 2016. West Nile virus disease cases and deaths
 reported to CDC by year and clinical presentation, 1999-2015. (accessed 18.08.16).

Acknowledgements

This work was supported by the Program for Leading Graduate Schools “Fostering Global Leaders
 in Veterinary Science for Contributing to One Health”, and grants (16H06429, 16H06431) from the
 Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. We thank Dr.
 Takashima for donating the WNV NY99 6-LP strain and Dr. Takada for providing pseudotyped
 VSV.

Author contributions statement

P. Wallaya, S.K., M.S., Y.O and H.S. conceived the experiments, P. Wallaya and S.K. conducted
 the experiments and analysed the data. P. Wallaya, S.K., M.S., Y.O., and H.S. contributed
 reagents/materials/analysis tools. P. Wallaya, S.K., M.C., W.H., Y.O. and H.S. wrote the paper. All
 authors reviewed the manuscript.

Additional information

Competing financial interests: The authors declare no competing financial interests.

Figure Legends

Fig. 1.

WNV infection is inhibited in the presence of VCP inhibitors. (A) WNV infection in the presence of either EerI (left panels) or MDBN (right panels). HeLa cells were inoculated with WNV (MOI=1) and then treated with EerI or MDBN at 1 h.p.i. Cells were harvested at 24 h.p.i. and stained with anti-JEV antibody (Kimura et al., 1994; Kobayashi et al., 2012) that has cross reactivity with WNV antigen (green). Cell nuclei were counterstained with DAPI (blue). (B) Positivity of WNV-infected cells from (A). Mean $\pm$ SD from triplicate experiments is shown; * $p < 0.05$, ** $p < 0.01$ (one-way ANOVA). (C) The culture supernatants from (A) were collected at 24 h.p.i. and the viral titers of the harvested supernatants were examined by plaque assay. Mean $\pm$ SD from three independent experiments is shown; * $p < 0.05$, ** $p < 0.01$ (one-way ANOVA).

Fig. 2.

WNV infection is inhibited in VCP knockdown cells. (A) HeLa cells were treated with either siRNA against VCP [siVCP (1), (2) and (3)] or control siRNA (siCont). The siRNA-treated cells were inoculated with WNV (MOI=1) at 48 h.p.i. The inoculated cells were harvested at 24 h.p.i. The expression of endogenous VCP protein and WNV envelope protein after treatment with the indicated siRNA were examined by immunoblotting with mouse anti-VCP antibody and mouse anti-WNV/Kunjin envelope protein. The expression of actin was examined after reprobing as an endogenous control. (B) WNV-infected cells from (A), after 24 h incubation with WNV, the cells were harvested and examined by immunofluorescence assay. WNV-infected cells were stained with anti-JEV antibody (green) and cell nuclei were counterstained with DAPI (blue). (C) Positivity of WNV-infected cells from (B). Mean $\pm$ SD from three independent experiments is shown; ** $p < 0.01$ (one-way ANOVA). (D) The culture supernatants from (A) were collected at 24 h.p.i and the

viral titers of the harvested supernatants were determined using plaque assay. Mean $\pm$ SD from three independent experiments is shown; ** $p < 0.01$ (one-way ANOVA).

Fig. 3.

The role of VCP in distinct steps of WNV life cycle was investigated. (A) WNV-VLP infection after the indicated siRNA treatment, HeLa cells were treated with siRNA against VCP, siVCP (1) or control siRNA (siCont). The indicated siRNA treated-cells were inoculated with WNV-VLPs (16 HAU) at 48 h post transfection and incubated for 72 h. Relative quantification of WNV-RNA normalized to human β -actin from (A) examined by qRT-PCR. Mean $\pm$ SD from three independent experiments is shown; ** $p < 0.01$ (one-way ANOVA). (B) Relative quantification of WNV-RNA expression levels normalized to human β -actin of siRNA-treated cells inoculated with WNV at the early time point of infection. siRNA-treated HeLa cells were inoculated with WNV after 48 h post siRNA transfection. The inoculated cells were incubated on ice for 1 h, followed by washing 5 times with PBS and then transferred to 37 °C. After 1 h incubation, the cells were harvested by trypsin and prepared for qRT-PCR. Mean $\pm$ SD from two independent experiments in triplicate is shown; * $p < 0.05$ (one-way ANOVA). (C) HeLa cells were treated with siRNA against VCP, siVCP (1) or control siRNA (siCont). After 24 h post transfection, the cells were transfected with plasmid set for WNV-VLP production and incubated for 72 h. The culture supernatants were harvested and inoculated on Vero cell monolayers in 10-fold serial dilutions. The viral titers of the harvested supernatants were determined as IFU/ml. Mean $\pm$ SD from three independent experiments is shown; ** $p < 0.01$ (one-way ANOVA). (D) HeLa cells were treated with siRNA, either siVCP (1) or siCont, and then transfected with plasmid containing WNV DNA replicon, pCMV-WNrep-DsRed at 24 h post siRNA treatment and incubated. The transfected cells were harvested at 72 h post transfection of pCMV-WNrep-DsRed. Relative quantification of WNV-RNA normalized to expression of human β -actin was examined by qRT-PCR. Mean $\pm$ SD from three independent experiments is shown; ** $p < 0.01$ (one-way ANOVA).

Figure 1




Figure 2






Figure 3



Supplementary Figure 1




Supplementary Fig. 1.


Cell viability of HeLa cells after treatment with either EerI or MDBN. The HeLa cells were treated with the indicated concentrations of either EerI (left) or MDBN (right). Cell viability was examined by a MTT assay at 24 h post treatment.

Supplementary Figure 2


A



B




C



Supplementary Fig. 2.

WNV infection in SK-N-SH cells is attenuated in the presence of EerI. (A) WNV infection in human neuroblastoma, SK-N-SH cells. SK-N-SH cells were inoculated with WNV (MOI=1). After 1 h.p.i., the inoculated-cells were treated with EerI at the indicated concentration. DMSO treated-cells were used as control. The cells were fixed and prepared for IFA at 24 h.p.i and stained with anti-JEV antibody which has cross reactivity with WNV antigen (green). Cell nuclei were stained with DAPI (blue). (B) Positivity of WNV-infected cells from (A). Mean $\pm$ SD from triplicate experiments is shown; * $p < 0.05$. ** $p < 0.01$ (one-way ANOVA). (C) Cell viability of SK-N-SH at 24 h after exposure to EerI with absorbance values obtained after MTT assay.


Supplementary Figure 3



Supplementary Fig. 3

Representative figure showing IFA results of WNV infection in siVCP (1) compared to siCont treated-HeLa cells at 12, 24 and 48 h.p.i. The HeLa cells were treated with either siVCP or siCont and then incubated at 37 °C for 48 h. Thereafter, the cells were infected with WNV (MOI=1) and incubated at 37 °C for 12, 24 and 48 h.p.i., respectively. After incubation at the indicated time points, the cells were then fixed and prepared for IFA followed by staining with anti-JEV antibody that has cross reactivity with WNV antigen (green). Cell nuclei were stained with DAPI (blue).

Supplementary Figure 4



Supplementary Fig. 4.

VCP knockdown does not affect infection of pseudotyped VSV. (A) HeLa cells were treated with siRNA against VCP (siVCP) or control siRNA (siCont) for 48 h. Thereafter, the siRNA-treated cells were inoculated with pseudotyped VSV. Pseudotyped VSV positive cells were determined by expression of green fluorescence protein (GFP), which was carried by the pseudotyped VSV replicon, at 8 h.p.i. nuclei were stained with DAPI (blue). (B) The positivity of GFP from (A). Mean $\pm$ SD from triplicate experiments is shown. The significance was analyzed using a one-way ANOVA.

Highlights

- Inhibition of VCP by chemical inhibitors decreased WNV infection in a dose-dependent manner.
- Knockdown of endogenous VCP level using siRNA suppressed WNV infection.
- Depletion of VCP levels suppressed WNV infection at the early stages of WNV replication cycle.
- Depletion of VCP levels lowered nascent WNV genomic RNA.
- VCP participates in early stages and viral genomic RNA replication.